Abstract
Peripheral arterial disease can cause devastating health outcomes, and few therapies are available to treat this condition. Results of a secondary analysis of the COMPASS trial suggest benefit with the use of rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily. This treatment regimen could change the standard pharmacotherapeutic management practice for many patients with peripheral arterial disease.
| Original language | American English |
|---|---|
| Journal | Journal of the American Academy of Physician Assistants |
| Volume | 32 |
| State | Published - Jul 1 2019 |
Disciplines
- Medicine and Health Sciences